Research ArticleArticle
Open Access
Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial
Arthur Kavanaugh, M. Elaine Husni, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Lenore Noonan and Elizabeth C. Hsia
The Journal of Rheumatology February 2019, jrheum.180681; DOI: https://doi.org/10.3899/jrheum.180681
Arthur Kavanaugh
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
M. Elaine Husni
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Diane D. Harrison
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Lilianne Kim
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Kim Hung Lo
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Lenore Noonan
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Elizabeth C. Hsia
From Internal Medicine — Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine — Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine — Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine — Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: ehsia@its.jnj.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.
Data supplements
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial
Arthur Kavanaugh, M. Elaine Husni, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Lenore Noonan, Elizabeth C. Hsia
The Journal of Rheumatology Feb 2019, jrheum.180681; DOI: 10.3899/jrheum.180681
Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial
Arthur Kavanaugh, M. Elaine Husni, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Lenore Noonan, Elizabeth C. Hsia
The Journal of Rheumatology Feb 2019, jrheum.180681; DOI: 10.3899/jrheum.180681